Inventor · disambiguated record
Juergen Michael Schanzer
Also filed as: SCHANZER JUERGEN MICHAEL
17 granted patents·19 pending applications·370 citations·filing 2009–2023
94Inventor score
Top patents by PatentIndex Score
36 records- 0197US11673945B2Bispecific antigen binding proteinsHOFFMANN LA ROCHE·Filed 2020·Granted Jun 13, 2023·4 cites·9 claims
- 0297US9382323B2Multispecific antibodies comprising full length antibodies and single chain fab fragmentsBRINKMANN ULRICH·Filed 2010·Granted Jul 5, 2016·77 cites·22 claims
- 0397US8268314B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2009·Granted Sep 18, 2012·70 cites·18 claims
- 0495US8703132B2Bispecific, tetravalent antigen binding proteinsIMHOF-JUNG SABINE·Filed 2010·Granted Apr 22, 2014·64 cites·11 claims
- 0594US9890204B2Trivalent, bispecific antibodiesBRINKMANN ULRICH·Filed 2012·Granted Feb 13, 2018·27 cites·11 claims
- 0694US8796424B2Tri- or tetraspecific antibodiesCROASDALE REBECCA·Filed 2010·Granted Aug 5, 2014·59 cites·26 claims
- 0794US8703130B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2012·Granted Apr 22, 2014·23 cites·12 claims
- 0892US9708396B2Bispecific anti-VEGF/anti-ANG-2 antibodiesHOFFMANN LA ROCHE·Filed 2014·Granted Jul 18, 2017·16 cites·17 claims
- 0988US9650442B2Bispecific anti-EGFR/anti IGF-1R antibodiesROCHE GLYCART AG·Filed 2014·Granted May 16, 2017·14 cites·6 claims
- 1084US10640555B2Bispecific antigen binding proteinsHOFFMANN LA ROCHE·Filed 2017·Granted May 5, 2020·2 cites·2 claims
- 1184US9879095B2Bispecific antibodies comprising a disulfide stabilized-Fv fragmentHOFFMANN LA ROCHE·Filed 2013·Granted Jan 30, 2018·5 cites·19 claims
- 1284US2023399391A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1381US9676845B2Bispecific antigen binding proteinsIMHOF-JUNG SABINE·Filed 2010·Granted Jun 13, 2017·5 cites·8 claims
- 1478US10584178B2Bispecific HER2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 10, 2020·2 cites·6 claims
- 1576US10106600B2Bispecific antibodiesBRINKMANN ULRICH·Filed 2011·Granted Oct 23, 2018·2 cites·11 claims
- 1675US2023119537A1Protease-activated t cell bispecific moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1773US2022275087A1Protease-activated t cell bispecific moleculesHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1872US2021047394A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 1970US11993642B2Trivalent, bispecific antibodiesHOFFMANN LA ROCHE·Filed 2019·Granted May 28, 2024·0 cites·10 claims
- 2064US11242390B2Protease-activated T cell bispecific moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Feb 8, 2022·0 cites·5 claims
- 2163US11787873B2Bispecific HER2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Oct 17, 2023·0 cites·17 claims
- 2262US2013156772A1Bispecific Anti ErbB1 / Anti cMet AntibodiesROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 2362US2013273054A1Bispecific Anti ErbB2/Anti cMet AntibodiesROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 2461US2017369566A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 2560US2022017640A1Activatable bispecific antibodiesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2659US2015191535A1Bispecific, bivalent anti-vegf/anti-ang2 antibodiesHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 2759US2018282399A1Trivalent, bispecific antibodiesHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 2855US2014135482A1Bispecific Anti ErbB3 / Anti cMet AntibodiesROCHE GLYCART AG·Filed 2014·Application pending·0 cites
- 2954US2010254988A1Bispecific Anti ErbB2 / Anti cMet AntibodiesBOSSENMAIER BIRGIT·Filed 2010·Application pending·0 cites
- 3054US2010254989A1Bispecific Anti ErbB1 / Anti c Met AntibodiesBOSSENMAIER BIRGIT·Filed 2010·Application pending·0 cites
- 3153US2015044214A1Bispecific, tetravalent antigen binding proteinsHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 3253US2015030598A1Tri- or tetraspecific antibodiesHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 3351US2017240626A1Bispecific, bivalent anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 3451US2010256340A1Trivalent, bispecific antibodiesBRINKMANN ULRICH·Filed 2010·Application pending·0 cites
- 3549US2013266568A1Activatable bispecific antibodiesROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 3644US2010256339A1Bispecific Anti ErbB3 / Anti cMet AntibodiesBOSSENMAIER BIRGIT·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Juergen Michael Schanzer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →